Repligen Q2 revenue rises 12% to $204 million and raises 2026 guidance
Repligen reported second-quarter 2026 revenue of $204 million, up 12% as reported and 13% organic, and raised its full-year 2026 organic growth and adjusted EPS guidance. GAAP net income fell to $5.0 million from $14.9 million, and GAAP EPS fell to $0.09 from $0.26, while adjusted EPS rose to $0.54 from $0.37. The release also announced a definitive agreement to acquire BioLife Solutions.
Key points
- Q2 2026 revenue was $204 million versus $182 million a year earlier, up 12% as reported and 13% organic.
- GAAP diluted EPS was $0.09 versus $0.26; adjusted diluted EPS was $0.54 versus $0.37.
- FY26 guidance raised: organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09.
- Cash, cash equivalents and marketable securities were $810 million at June 30, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 28, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.